1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Ligand Pharmaceuticals, Inc.

Ligand Pharmaceuticals, Inc.

LGNZZ
Ligand Pharmaceuticals, Inc.US flagOther OTC
0.06
USD
+0.00
- -
1.20MMarket Cap
Ligand Pharmaceuticals, Inc.
LGNZZ
(Other OTC)

Recent

price

0.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

2000
2001
2002
2003
2004
2005
2006
2007
2008
TTM
FRC
9.18
9.23
1.8
6.34
0.68
0.19
0.15
0.29
0.14
0.52
Revenue per Share
-13.05
-4.44
-10.12
-23.84
-1.49
-1.2
-1.15
-1.37
-1.25
-0.35
Basic EPS, GAAP
- -
- -
-5.12
-11.55
-1.38
-0.88
-1.05
-1.26
-0.99
-0.56
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-26.34
-17.07
-21.32
-25.27
-5.12
-3.8
-3.73
-4.9
-5.69
-5.54
Book Value per Share
14.94
25.87
6.89
16.23
4.17
3.02
2.35
1.05
0.1
0.08
Tangible Book Value per Share
- -
1
1
1
10
20
29
31
34
35
Basic Weighted Avg Shares
4
8
2
9
7
4
4
9
5
18
Sales/Revenue/Turnover
-149.38
-51.29
-565.63
-102.84
-223.42
-654.12
-839.24
-491.61
-879.36
-63.88
Operating Margin (%)
- -
- -
- -
1
3
3
1
- -
2
2
Depreciation Expense
-5
-4
-13
-9
-15
-24
-33
-42
-42
-12
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-142.13
-48.04
-561.76
-103.34
-218.98
-625.3
-758.5
-463.45
-879.71
-67.66
Profit Margin (%)
- -
- -
14
22
41
60
69
32
9
3
Working Capital
- -
- -
2
1
1
2
4
4
5
- -
LT Debt
6
21
9
23
42
60
68
32
3
3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'09
Jun'09
Sep'09
ST Debt
8
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
35
Market Capitalization
25
20
15

Working Capital

FRC

•

in mil. unless spec.
Mar'09
Jun'09
Sep'09
Total Current Assets
13
7
4
Cash, Cash Equivalents & STI
12
7
2
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
16
7
1
Payables & Accruals
4
2
1
ST Debt
8
- -
- -
Deferred Revenue
5
5
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-1.41%
-89.47%
Free Cash Flow
- -
19.66%
-13.09%
Net Income, GAAP
- -
36.85%
1.23%
Sales/Revenue/Turnover
- -
1.07%
-46.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2007
3
2
3
1
9
2008
1
1
1
2
5
2009
2
10
5
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2007
-0.28
-0.4
-0.34
- -
-1.37
2008
-0.36
-0.34
-0.28
- -
-1.25
2009
-0.23
0.09
0.08
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -
Similar Companies
Blueprint Medicines Corporation (0HOJ.L)
Zenith Healthcare Limited (ZENITHHE.BO)
Denis Chem Lab Limited (DENISCHEM.BO)
Bristol-Myers Squibb Company (BMY.SW)
Great Tree Pharmacy Co., Ltd. (6469.TWO)
Shelter Pharma Ltd. (SHELTER.BO)
Business
Ligand Pharmaceuticals Incorporated (NasdaqCM: LGND) develops and acquires technologies that help pharmaceutical companies discover and develop medicines worldwide. The company offers Captisol-enabled products, including Kyprolis, a proteasome inhibitor for multiple myeloma treatment; Novartis' Vidaza and Dacogen, hypomethylating agents for myelodysplastic syndromes; Baxter's Abraxane, an albumin-bound chemotherapy for breast, lung, and pancreatic cancers; and other Captisol-enabled formulations such as AmBisome for fungal infections and REZLIDHIA for acute myeloid leukemia. Ligand provides the Pelican platform for expression of difficult-to-express proteins; the OmniAb platform, a transgenic animal-based antibody discovery technology encompassing OmniChicken, OmniRat, OmniMouse, and OmniFlic offerings; and Filancyl polymer technology for dermal fillers. The company operates primarily in the United States, Europe, and Asia, with headquarters in Carlsbad, California, where it was founded in 1987. In recent developments, Ligand has expanded through strategic partnerships and licensing deals, including collaborations for antibody discovery using OmniAb and new Captisol-enabled drug formulations launched in partnership with major pharmaceutical firms over the past two years.